Chung Eun Jee, Freeman William R, Azen Stanley P, Lee Hyo, Koh Hyoung Jun
Department of Ophthalmology, NHIC Ilsan Hospital, Gyounggi-do, Korea.
Yonsei Med J. 2008 Dec 31;49(6):955-64. doi: 10.3349/ymj.2008.49.6.955.
To compare the efficacy of posterior sub-Tenon's capsule triamcinolone acetonide injection combined with modified grid macular photocoagulation (PSTI + MP) with intravitreal triamcinolone acetonide (IVTA) injection in the treatment of diffuse diabetic macular edema (DME).
Forty eyes of 33 patients with diffuse DME were randomly allocated into either PSTI + MP (20 eyes) or IVTA (20 eyes). Best corrected visual acuity (VA) and foveal thickness were measured.
The ETDRS scores at baseline were 25.2 +/- 13.6 (mean +/- SD) letters in the PSTI + MP group, whereas 21.7 +/- 16.3 letters in the IVTA group. The ETDRS scores improved by 33.2 +/- 15.9, 34.7 +/- 16.6 and 30.9 +/- 19.0 letters in the PSTI + MP group whereas by 30.9 +/- 15.4, 30.1 +/- 17.9 and 31.5 +/- 15.0 letters in the IVTA group at 1, 3, and 6 months after the treatments, respectively. The VA improved significantly at 1 month and 3 months after both treatments (all p < 0.02, paired t-test). The VA improvements were no longer significant at 6 months in either group. There were no statistically significant differences at any time points between the 2 groups (all p > 0.05, Student's t-test). The foveal thicknesses at baseline and 1, 3, and 6 months after the treatments were 382.8 +/- 148.3, 309.1 +/- 131.3, 319.3 +/- 93.3, 340.4 +/- 123.5 microm (mean +/- SD) in the PSTI + MP group vs. 369.1 +/- 123.1, 241.4 +/- 52.3, 277.5 +/- 137.4, 290.2 +/- 127.9microm in the IVTA group, respectively. Pairwise comparisons revealed significant decrease in foveal thickness at 1 month (p = 0.01, paired t-test) for the PSTI + MP group, and at both 1 month (p < 0.001) and 3 months (p = 0.016) for the IVTA group. There were no statistically significant differences at any time points between the 2 groups (all p > 0.05, Student's t-test). In contrast to the PSTI + MP group, where no complications were noted, the elevation of intra-ocular pressure in 3 of 20 eyes (15%) and a significant increase in average cataract grading were observed in the IVTA group.
PSTI + MP treatment provides significant improvement of vision in patients with diffuse DME over 3 months, and achieves outcomes comparable to those after IVTA treatment, however, with fewer complications.
比较后Tenon囊下注射曲安奈德联合改良格栅样黄斑光凝术(PSTI + MP)与玻璃体内注射曲安奈德(IVTA)治疗弥漫性糖尿病性黄斑水肿(DME)的疗效。
将33例弥漫性DME患者的40只眼随机分为PSTI + MP组(20只眼)和IVTA组(20只眼)。测量最佳矫正视力(VA)和黄斑中心凹厚度。
PSTI + MP组基线时ETDRS视力表评分平均为25.2±13.6(均值±标准差)字母,IVTA组为21.7±16.3字母。治疗后1、3和6个月时,PSTI + MP组ETDRS视力表评分分别提高了33.2±15.9、34.7±16.6和30.9±19.0字母,IVTA组分别提高了30.9±15.4、30.1±17.9和31.5±15.0字母。两种治疗后1个月和3个月时VA均显著改善(所有p < 0.02,配对t检验)。6个月时两组VA改善均不再显著。两组在任何时间点均无统计学显著差异(所有p > 0.05,Student t检验)。PSTI + MP组治疗前、治疗后1、3和6个月时黄斑中心凹厚度分别为382.8±148.3、309.1±131.3、319.3±93.3、340.4±123.5微米(均值±标准差),IVTA组分别为369.1±123.1、241.4±52.3、277.5±137.4、290.2±127.9微米。两两比较显示,PSTI + MP组1个月时黄斑中心凹厚度显著降低(p = 0.01,配对t检验),IVTA组1个月(p < 0.001)和3个月(p = 0.016)时黄斑中心凹厚度均显著降低。两组在任何时间点均无统计学显著差异(所有p > 0.05,Student t检验)。与PSTI + MP组未观察到并发症不同,IVTA组20只眼中有3只眼(15%)眼压升高,平均白内障分级显著增加。
PSTI + MP治疗可使弥漫性DME患者在3个月内视力显著改善,疗效与IVTA治疗相当,但并发症较少。